Table 3.
Results for changes in management plans.
| Author and Year | Cancer Type | Proportion of Cases with Changed Overall Management Plans | Proportion of Changed Cases Stratified per Stage or MDTM Type | Type of Changes |
|---|---|---|---|---|
| Acher et al., 2005 [48] | Urological cancers (prostate cancer) | 1.6% * | - | - |
| Chinai et al., 2013 [19] | Colorectal cancer | 6.4% | - | - |
| De Luca et al., 2019 [49] | Prostate cancer | 35.8% * | Local disease: 23.2%, advanced disease: 46.9%, metastatic disease: 33.4% |
- |
| El Khoury et al., 2016 [50] | Urological cancers (prostate cancer) | 42.7% | Gleason score 6: 27.3% Gleason score 7: 51.7% Gleason score 8: 44.4% Gleason score 9: 50.0% Gleason score 10: 40.0% |
- |
| Fernando et al., 2017 [20] | Colorectal cancer | 23% | - | Proportion of changed clinical staging cases: 4% |
| Jung et al., 2018 [21] | Colorectal cancer | 12.9% | Newly diagnosed cancer: 7.6%, recurrence cancer patients: 16.4% (p < 0.001) |
Treatment plans overall: 12.9% Nonsurgical treatment in 66.5% of cases, modifications to the surgical approach: 3.4% no treatment: 30.2%. |
| Karagkounis et al., 2018 [22] | Rectal cancer | 26.1% | Initial discussion: 32.4%, Follow-up discussions: 35.2%, Postoperative discussions: 6.3% (p < 0.001) |
Diagnostic plan: 9.7% * of cases Treatment plans: 20.5% * Decided to operate: 2.1% * of cases; Decided not to operate: 12.4% *; Changed operative approach: 18.6% *. Neoadjuvant therapy added: 39.2% *; Adjuvant therapy added: 6.2% *. Additional workup biopsy/pathology: 10.3% *; Additional workup imaging: 26.8% *. Changes were more frequent when the pre-MDTM plan was considered tentative by the attending physician (45.5%, p < 0.001). |
| Kurpad et al., 2011 [51] | Urological cancers (prostate cancer) | 50% | - | Treatment changed in 18.5%, diagnosis changed in 6.5%, both diagnosis and treatment changed in 3.3%, other changes in 7.6% and N/A in 14.1% of cases. |
| Murthy et al., 2014 [54] | Breast cancer | 42% | Stage 0: 21%, stage IA: 27%, stage IB: 8%, stage IIA: 15%, stage IIB: 17%, stage IIIA: 7%, stage IIIB: 0%, stage IIIC: 1%, stage IV: 2%. |
Surgical treatment: 38.2% of all changes. medical management (chemotherapy/endocrine therapy): 33.3% Radiation treatment: 16.6% Combined medical and radiation therapy: 6.8% Imaging changes (e.g., MRI, mammogram): 4.9% |
| Rao et al., 2014 [52] | Urological cancers (prostate cancer) | 26% | T1: 0%, T2: 25%, T3: 21% (p = 0.62). Localized disease: 23% Metastatic disease: 38% (p < 0.05). |
- |
| Scarberry et al., 2018 [53] | Genitourinary cancers (Prostate) | 17.6% | - | - |
| Schmidt et al., 2015 [42] | Lung cancer | 53% | - | Changes in treatment: 41% of cases Staging recommendations changed: 59% of cases |
| Snelgrove et al., 2015 [30] | Rectal cancer | 29% | - | Changes in initial treatment: Primary surgery 58% * Neoadjuvant chemoradiation: 25% * Systemic chemotherapy: 16.7% * |
| Ung et al., 2016 [45] | Lung cancer | 58% | - | Additional investigations: 59% Treatment modality: 19% Treatment intent: 9% Tumor histology: 6% Tumor stage: 6% |
* These values were calculated by the authors (L.K. and H.W.). Results, if available, comparing patients in MDTM group and non-MDTM group, are shown as (‘results non-MDTM group’ vs. ‘results MDTM group’, p-value). MDTM = multidisciplinary team meeting.